atorvastatin

P2/3, N=135, Recruiting, Novartis Pharma AG

P4, N=80, Not yet recruiting, Fayoum University

In xenografts, atorvastatin suppressed ULMS tumor growth by ~50% with minimal toxicity, as evidenced by normal serum ALT and creatinine levels and preserved organ histology. These findings identify protein geranylgeranylation as a novel therapeutic vulnerability in ULMS and support statin repurposing as a promising treatment strategy.

P1/2, N=40, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P=N/A, N=5000, Not yet recruiting, Samsung Medical Center

P=N/A, N=80, Not yet recruiting, University of Medicine and Pharmacy at Ho Chi Minh City

He had been taking almonertinib for 26 months, hybutimibe for 3 months and alirocumab for 1 month prior to admission. Almonertinib is a moderately sensitive substrate of CYP3A4, thereby may elevate statin concentration and increase the likelihood of developing myopathy. For patients who need to take almonertinib and cholesterol-lowering drugs simultaneously, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and cholesterol absorption inhibitors (such as ezetimibe and hybutimibe) can be considered instead of atorvastatin for the reduction of cardiovascular events.

P1, N=12, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

Animal experiment demonstrated significant DDIs between two drugs no matter single dose or multiple doses were administered, which obviously increased the drug exposure and inhibited elimination. Close attention should be paid to the combination regimens of these two drugs in clinical practice.

In a nutshell, the proposed combination of ATST and SOR presents a compelling strategy to trigger a dual cell death mechanism, thereby amplifying the efficacy and anti-metastatic potential in CRC. Nonetheless, the safety concerns warrant continued investigation into advanced drug delivery systems to boost efficacy and clinical usage of the present combination.

P1, N=16, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.

P4, N=70, Not yet recruiting, Oslo University Hospital HF